An oil-in-water emulsion composition that has zinc chloride as an active component and provides excellent separation inhibiting properties and/or drug release properties. The oil-in-water emulsion composition comprises: (A) not less than 30 wt % of zinc chloride; (B) an oily base selected from the group consisting of hydrocarbon oils and higher alcohols; (C) a non-ionic surfactant; and (D) an aqueous base selected from the group consisting of water and polyalcohols. The content of (B) with respect to 100 parts by weight of the components (B) and (C) combined is not less than 52 parts by weight. The content of (B) with respect to 100 parts by weight of the component (B) and the component (D) combined is not less than 11.7 parts by weight. The oil-in-water emulsion composition has excellent separation inhibiting properties. When the component (D) is water and polyethylene glycol, the oil-in-water emulsion composition has excellent drug release properties.
A viscoelastic composition for securing the field of view of an endoscope, the viscoelastic composition comprising a thickening substance and water and having a shear storage modulus G′ of 0.7 Pa or more, and a method for securing the field of view of an endoscope, the method comprising feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.
A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
A61B 1/012 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments caractérisés par les conduits internes ou par leurs accessoires
According to the present invention, a syringe comprising a barrel having a spout and an opening; a gasket slidably accommodated in the barrel; a plunger connected to the gasket; and a cap that seals the spout of the barrel, wherein the opening of the barrel is sealed only with the gasket. The syringe is excellent in usability, durability, and safety.
A61J 1/05 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques pour recueillir, stocker ou administrer du sang, du plasma ou des liquides à usage médical
A method for producing a marked product comprises: transporting an object along a transport path; disposing a beam-forming mechanism between a laser oscillator and the transport path, the beam-forming mechanism forming a regular intensity distribution of laser light emitted from the laser oscillator by branching the laser light according to a prescribed pattern or blocking some of the laser light according to a prescribed pattern; disposing a mask member between the laser oscillator and the transport path, the mask member having formed thereon a transmission pattern corresponding to the design of a marking to be applied to the object; and generating laser light from the laser oscillator and irradiating the object being transported with the laser light that has passed through the beam-forming mechanism and the mask member. The travel direction of the laser light emitted from the beam-forming mechanism is one direction and is the same as the travel direction of the laser light incident on the beam-forming mechanism.
B23K 26/00 - Travail par rayon laser, p. ex. soudage, découpage ou perçage
B23K 26/064 - Mise en forme du faisceau laser, p. ex. à l’aide de masques ou de foyers multiples au moyen d'éléments optiques, p. ex. lentilles, miroirs ou prismes
B23K 26/066 - Mise en forme du faisceau laser, p. ex. à l’aide de masques ou de foyers multiples au moyen d'éléments optiques, p. ex. lentilles, miroirs ou prismes par utilisation de masques
The present invention realizes a breaker of which the outer shape is miniaturized while ensuring reliable connection of an elastic arm plate and a terminal plate and arrangement thereof in a fixed position of a case, thus being most suitable for surface mount device (SMD) applications. The breaker comprises a fixed contact metal plate 4 having a fixed contact 5, an elastic arm plate 6 having a movable contact 7, a terminal plate 3 to which the elastic arm plate 6 is fixed, a case 1, and a bimetal 8 for switching the movable contact 7 from on to off. The case 1 is made of plastic and has a hollow storage space 20 inside. Connection terminals 4X, 3X are disposed at respective end parts 1C of the bottom surface of the case 1. The terminal plate 3 includes a lower welding plate 3A to which an upper welding plate 6B is welded in a laminated state via laser welding sections 30. The connection terminals 3X are connected to the side edges of the lower welding plate 3A, which extends in the width direction of the case 1, via rising sections 3B. The rising sections 3B are embedded in the case 1. The lateral width (W1) of the lower welding plate 3A is wider than the lateral width (W2) of the upper welding plate 6B.
The container body has a body part including an upper part positioned closer to a neck part, a lower part positioned closer to a bottom part, and a central part positioned between the upper part and the lower part. The body part has an oval shape having a short diameter and a long diameter in a cross section perpendicular to a center axis, and includes a pair of first side surfaces disposed at both ends of the short diameter, and a pair of second side surfaces disposed at both ends of the long diameter. The body part has a pair of buckling prevention parts formed continuously in the center axis direction on the pair of second side surfaces of the central part.
The primary purpose of the present invention is to provide, for albumin deficiency symptoms which requires administration of zinc, a formulation that is capable of further improving the efficiency of zinc replenishment. The secondary purpose of the present invention is to provide a formulation that has a treatment effect for iron overload disorders. In the present invention, a first pharmaceutical composition, for intravenous injection and containing zinc ions and serum albumin, is capable of more efficiently replenishing zinc for albumin deficiency symptoms that requires administration of zinc, and a second composition, for intravenous injection and containing zinc ions, is capable of removing iron in vivo for iron overload disorders.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
The present invention addresses the problem of providing an emulsified nutritional composition having excellent emulsion stability and having total calories of 0.9 kcal/mL or greater, where the ratio of lipid calories to total calories is 40% or greater. This emulsified nutritional composition contains protein and lipid, and has total calories of 0.9 kcal/mL or greater, where the ratio of lipid calories to total calories is 40% or greater. The protein contains collagen peptides having a weight-average molecular weight of 3000 or less.
A23L 33/115 - Acides gras ou leurs dérivésGraisses ou huiles
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
The present invention addresses the problem of providing: an excellent agent that has an energy consumption promoting action, suppresses an increase in body weight and body fat percentage, and/or can contribute to prevention or amelioration of obesity; and a pharmaceutical composition or a food composition containing the agent. The problem can be solved by using a compound represented by formula (A).
A61K 31/4015 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant des groupes oxo liés directement à l'hétérocycle, p. ex. piracétam, éthosuximide
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
To provide a light guide used to facilitate insertion of a medical tube into a body of a patient.
To provide a light guide used to facilitate insertion of a medical tube into a body of a patient.
[SOLUTION] A light guide to be used for inserting a medical tube into a body for nasogastric tube feeding, the light guide including: a main body part having a long length, the main body part being configured to guide light entering a proximal end part from a light source device, to emit resultant light from a distal end part, wherein the main body part includes a linear part having a predetermined length from the distal end part, and a curved part continuous with the linear part, the curved part having a predetermined curvature radius, the linear part has a length in a range of from 40 mm to 100 mm, and the curved part has a curvature radius in a range from 105 mm to 225 mm
An antiseptic composition with a more extended applicable range by further enhancing the efficacy of olanexidine gluconate, which has been used as a highly safe dermal bactericidal disinfectant, and extending antibacterial spectrum. The antiseptic composition includes olanexidine gluconate and is basic and has a more extended bactericidal spectrum than conventional disinfectants.
METHOD FOR PRODUCING A MICROORGANISM HAVING N-DEACETYLATION ACTIVITY AND N-SULFATION ACTIVITY, METHOD FOR PRODUCING A HEPAROSAN-DERIVED COMPOUND, AND A MICROORGANISM HAVING N-DEACETYLATION ACTIVITY AND N-SULFATION ACTIVITY
The present invention relates to a method for producing a microorganism having N-deacetylation activity and N-sulfation activity, including a step (I) of modifying a nucleotide sequence of a DNA encoding N-deacetylase/N-sulfotransferase, and a step (II) of introducing the DNA containing the nucleotide sequence modified in the step (I) into a microorganism in an expressible manner, wherein the step (I) is a step of performing codon optimization according to the codon usage frequency of a biological species different from the microorganism. Further, the invention relates to a method for producing a microorganism having N-deacetylation activity and N-sulfation activity, including a step (i) of expressing a specific protein in a microorganism.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Infusion solutions; Dietetic foods and beverages adapted for medical use; Health food supplements; Dietary and nutritional supplements; Pharmaceutical preparations for the treatment of obesity; Cell preparations, namely, animal cells for the treatment of diseases and conditions; Living tissues, namely, animal tissues from which cells can be harvested for the treatment of diseases and conditions; Pharmaceutical preparations and substances for the treatment of diabetes; Chemical preparations for medical use, namely, transparent gels for ensuring visual field in endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology; Chemical preparations for medical purposes for use in the field of endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology. Medical light sources and gastroesophageal sterile tubes and catheters; Endoscopy cameras for medical purposes; medical apparatus and instruments for ensuring visual field in endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology. Medical services; Medical information; Medical examination; Medical and pharmaceutical consultation; Dietary and nutritional guidance
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Infusion solutions; Dietetic foods and beverages adapted for medical use; Health food supplements; Dietary and nutritional supplements; Pharmaceutical preparations for the treatment of obesity; Cell preparations, namely, animal cells for the treatment of diseases and conditions; Living tissues, namely, animal tissues from which cells can be harvested for the treatment of diseases and conditions; Pharmaceutical preparations and substances for the treatment of diabetes; Chemical preparations for medical use, namely, transparent gels for ensuring visual field in endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology; Chemical preparations for medical purposes for use in the field of endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology Medical light sources and gastroesophageal sterile tubes and catheters; Endoscopy cameras for medical purposes; medical apparatus and instruments for ensuring visual field in endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology Medical services; Medical information; Medical examination; Medical and pharmaceutical consultation; Dietary and nutritional guidance
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Infusion solutions; Dietetic foods and beverages adapted for medical use; Health food supplements; Dietary and nutritional supplements; Pharmaceutical preparations for the treatment of obesity; Cell preparations, namely, animal cells for the treatment of diseases and conditions; Living tissues, namely, animal tissues from which cells can be harvested for the treatment of diseases and conditions; Pharmaceutical preparations and substances for the treatment of diabetes; Chemical preparations for medical use, namely, transparent gels for ensuring visual field in endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology; Chemical preparations for medical purposes for use in the field of endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology. Medical light sources and gastroesophageal sterile tubes and catheters; Endoscopy cameras for medical purposes; medical apparatus and instruments for ensuring visual field in endoscopic examination and treatment when diagnosing and treating organs of the digestive, respiratory, urogenital, and endocrine systems as well as the spleen, the heart, great vessels, and hollow and multilayered walled organs studied in splanchnology. Medical services; Medical information; Medical examination; Medical and pharmaceutical consultation; Dietary and nutritional guidance
The object of the present invention is to provide an antiseptic composition that can reduce the risk of an incise drape coming off from the skin, without adversely affecting microbicidal activity, even when the incise drape is affixed to skin surface after application of the antiseptic composition, and/or exerts more effective microbicidal activity. A composition comprising a microbicide and a sugar alcohol is used as the antiseptic composition.
A01N 25/02 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles contenant des liquides comme supports, diluants ou solvants
A01P 1/00 - DésinfectantsComposés antimicrobiens ou leurs mélanges
A61L 24/00 - Adhésifs ou ciments chirurgicauxAdhésifs pour dispositifs de colostomie
An object of the present invention is to provide a new method for providing nutritional supplementation to a subject in poor nutrition state while preventing or suppressing refeeding syndrome, and an enteral nutrient preparation that can be used in the method. As a means for solving the problem, provided is the enteral nutrient preparation including protein and a lipid, and an amino acid as necessary, in which 90 wt % or more of the protein is not milk-derived protein, and (a) an amino acid score of a mixture of the protein and the amino acid is 100 and a lipid calorie ratio is 40% or more, or (b) an amino acid score of a mixture of the protein and the amino acid is less than 100 and a lipid calorie ratio is 15% or more.
An objective of the present invention is to provide an adhesion preventing material exhibiting an excellent adhesion preventing effect. The adhesion preventing material contains a crosslinked gelatin gel having an uncrosslinked lysine residue number of 1.15×10-4mol/g to 2.50×10-4mol/g.
A61L 31/12 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; lacteal flour for babies; nutritional supplements consisting primarily of proteins, fats and/or carbohydrates in liquid, jelly or gel form; nutritional supplements; dietary supplements for humans
29 - Viande, produits laitiers et aliments préparés ou conservés
30 - Aliments de base, thé, café, pâtisseries et confiseries
32 - Bières; boissons non alcoolisées
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Jellies for food; jellies, jams, compotes; gelatine for food; meat jellies; fish jellies; fruit jellies; vegetable jellies; kanten [dried pieces of agar jelly]; meat jellies containing collagen peptides; fish jellies containing collagen peptides; fruit jellies containing collagen peptides; vegetable jellies containing collagen peptides; protein milk; soya milk in jelly; soya-based snack foods; milk-based beverages flavored with coffee; milk-based beverages containing fruit juice; fruit-based, vegetable-based, bean-based or nut-based snacks Puddings; jellies [confectionery]; bavarian creams; confectionery; bread and buns; porridge; processed grains; boxed lunches consisting of rice, with added meat, fish or vegetables; instant confectionery mixes; ice cream mixes; sherbet mixes; coffee; cocoa; tea; sweets; artificial coffee; pastries; processed cereals; preparations made from rice; wheat, processed; ready-to-eat cereals; gluten-free cereal products; cereal bars Soft drinks; fruit juices; vegetable juices [beverages]; whey beverages; beer; extracts of hops for making beer; fruit and vegetable smoothies; non-alcoholic beverages for nutritional purposes; non-alcoholic beverages; smoothies; energy drinks; isotonic beverages; soft drinks in jelly; fruit juices in jelly; vegetable juices in jelly [beverages]; whey beverages in jelly; isotonic beverages in jelly; concentrates, syrups and powders used in the preparation of soft drinks; syrups and other non-alcoholic preparations for making beverages; powders used in the preparation of non-alcoholic beverages for nutritional purposes; powders used in the preparation of fruit-based beverages; syrups for beverages; soft drinks in powder form; fruit juices in powder form; vegetable juices in powder form [beverages]; whey beverages in powder form; isotonic beverages in powder form; non-alcoholic beverages, other than for dietary or medical purposes; powder used in the preparation of non-alcoholic beverages, other than for dietary or medical purposes; soft drink mixes; non-carbonated soft drinks; coffee-flavored soft drinks; fruit-flavored soft drinks; vitamin fortified soft drinks; sports drinks Dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; food for babies; lacteal flour for babies; dietary and nutritional supplements consisting primarily of proteins, fats and/or carbohydrates in liquid, jelly, gel or powder form; dietary and nutritional supplements; dietary supplement drinks; dietary supplement drink mixes; powdered nutritional supplement drink mix
22.
MEDICAL CAP, MEDICAL CONTAINER, AND PRODUCTION METHOD FOR MEDICAL CONTAINER
This medical cap is provided with: a stopper that is disposed inside a cylindrical mouth part having an opening formed therein; and a case. The case includes: a cylindrical inner wall that is disposed between the stopper and the mouth part in a state of being in contact with the stopper and the mouth part; and a cylindrical outer wall that encloses the inner wall having therebetween a cylindrical space in which the mouth part is accommodated. The inner wall includes thin-wall portions and thick-wall portions that have mutually different thicknesses in the radial direction of the case. The thin-wall portions and the thick-wall portions are arranged side by side in the circumferential direction of the case.
A61J 1/05 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques pour recueillir, stocker ou administrer du sang, du plasma ou des liquides à usage médical
23.
MEDICAL CAP, MEDICAL CONTAINER, AND METHOD FOR MANUFACTURING MEDICAL CAP
A medical cap according to the present invention comprises: a plug disposed inside a cylindrical mouth part that forms an opening; and a case provided with a cylindrical inner wall disposed between the plug and the mouth part, a cylindrical outer wall surrounding the inner wall across a cylindrical space accommodating the mouth part, and a top wall disposed above the mouth part disposed in the cylindrical space. The plug includes an inside section surrounded by the inner wall and a lower section disposed between the top wall and the mouth part disposed in the cylindrical space.
A61J 1/05 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques pour recueillir, stocker ou administrer du sang, du plasma ou des liquides à usage médical
Provided are a liquid agent container formed of a multilayer film using polybutylene terephthalate in an outer layer, in which it is controlled or prevented that a component derived from the polybutylene terephthalate is permeates the multilayer film and is eluted into a content liquid, and a multilayer film for forming such a liquid agent container. A multilayer film includes at least a layer (1) including polybutylene terephthalate, a layer (2) including a cyclic olefin-based polymer, a flexible layer (3) including an ethylene-based resin, and a layer (4) including a polyolefin, which are laminated, wherein the layer (1), the layer (2), and the layer (4) forming one surface of the multilayer film are laminated in this order, and a liquid agent container is formed of the multilayer film so that the layer (4) is formed as the innermost layer.
B32B 27/36 - Produits stratifiés composés essentiellement de résine synthétique comprenant des polyesters
B32B 27/08 - Produits stratifiés composés essentiellement de résine synthétique comme seul composant ou composant principal d'une couche adjacente à une autre couche d'une substance spécifique d'une résine synthétique d'une sorte différente
B32B 27/32 - Produits stratifiés composés essentiellement de résine synthétique comprenant des polyoléfines
B32B 37/06 - Procédés ou dispositifs pour la stratification, p. ex. par polymérisation ou par liaison à l'aide d'ultrasons caractérisés par le procédé de chauffage
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Non-alcoholic beverages for providing and maintaining water and electrolytes in cases of dehydration; non-alcoholic isotonic beverages; sports drinks containing electrolytes; non-alcoholic isotonic gel beverages; non-alcoholic isotonic jelly beverages; powders for making isotonic drinks Electrolyte drinks for medical purposes; dietetic beverages adapted for medical purposes; nutritional supplements; oral rehydration solution for medical purposes; oral rehydration drinks for providing and maintaining water and electrolytes in cases of dehydration; oral rehydration solution for medical purposes in the form of gels; oral rehydration solution for medical purposes in jelly form; powdered nutritional supplement drink mix
The present invention relates to: a carbonated jelly beverage for suppressing water consumption; a carbonated jelly beverage for alleviating thirst; a powder preparation for producing these carbonated jelly beverages; a water consumption suppression method comprising consumption of a carbonated jelly beverage; and a thirst alleviation method comprising consumption of a carbonated jelly beverage.
Problem
Problem
To provide a novel cold medicine or antiviral agent.
Problem
To provide a novel cold medicine or antiviral agent.
Means for Solution
Problem
To provide a novel cold medicine or antiviral agent.
Means for Solution
A cold medicine comprising a compound represented by formula (1) or a pharmaceutically acceptable salt thereof.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61P 31/14 - Antiviraux pour le traitement des virus ARN
An anti-reflective structural body includes a main body constituted of a raw material that contains a color material of black color and an anti-reflective structure formed on an outer surface of the main body, the anti-reflective structure includes a plurality of recesses each being formed to be recessed with respect to the outer surface and a base portion forming boundary portions of the recesses that are mutually adjacent and having a top portion on the outer surface, a profile curve of the base portion in a depth direction of the recesses includes the top portion formed to a curved shape, and virtual circles respectively including portions of the top portion of the curved shape as circular arcs each have a diameter ϕ of not more than 50 μm.
Provided is a means for more efficiently transplant an encapsulated islet. A liquid for preservation or transplantation of an encapsulated islet, said liquid containing trehalose, a derivative thereof or a salt of the same.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Dietetic beverages adapted for medical purposes; dietetic
foods adapted for medical purposes; beverages for babies;
food for babies; lacteal flour for babies; nutritional
supplements consisting primarily of proteins, fats and/or
carbohydrates in liquid, jelly, gel or powder form;
nutritional supplements; dietary supplements for human
beings; dietary supplements for human beings, namely,
dietary supplement drinks, dietary supplement in liquid,
jelly, gel or powder form, and dietary supplement drink
mixes; nutritional supplements, namely, powdered nutritional
supplement drink mix.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Dietetic foods adapted for medical purposes; dietetic
beverages adapted for medical purposes; beverages for
babies; food for babies; lacteal flour for babies;
nutritional supplements consisting primarily of proteins,
fats and/or carbohydrates in liquid, jelly, gel or powder
form; nutritional supplements; dietary supplements for
humans; pharmaceutical preparations.
The present invention addresses the problem of providing: a cell cryopreservation liquid which can effectively inhibit mammalian cell death caused by freezing and thawing of the cells and which can effectively increase the proliferation ability of mammalian cells after freezing and thawing; and a cryopreservation method for mammalian cells, in which the cell cryopreservation liquid is used. In the present invention, a liquid comprising 2.5-8.75 (v/v)% propylene glycol is used as a mammalian cell cryopreservation liquid.
The present invention provides a resin product comprising a wall. The wall has a code area including a plurality of machined areas where protrusions and recesses are formed, and a transparent unmachined area, adjacent to the machined areas, where the protrusions and recesses are not formed. The reflectance of light in the machined areas is higher than the reflectance of light in the unmachined area, and the code area shows an optically readable information code.
G06K 19/06 - Supports d'enregistrement pour utilisation avec des machines et avec au moins une partie prévue pour supporter des marques numériques caractérisés par le genre de marque numérique, p. ex. forme, nature, code
B65D 23/00 - Parties constitutives des bouteilles ou des pots non prévues ailleurs
The purpose of the present invention is to provide a formulation which is for producing an oil-in-water emulsion composition that has zinc chloride as an active component and which provides excellent separation inhibiting properties and/or drug release properties. Provided is an oil-in-water emulsion composition comprising: (A) not less than 30 mass% of zinc chloride; (B) an oil-based base selected from the group consisting of hydrocarbon oils and higher alcohols; (C) a non-ionic surfactant; and (D) an aqueous base selected from the group consisting of water and polyalcohols. The content of (B) with respect to 100 parts by weight of the component (B) and the component (C) combined is not less than 52 parts by weight. The content of (B) with respect to 100 parts by weight of the component (B) and the component (D) combined is not less than 11.7 parts by weight. Thus, the oil-in-water emulsion composition has excellent separation inhibiting properties. When the component (D) is water and polyethylene glycol, the oil-in-water emulsion composition has excellent drug release properties.
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
The present invention provides a syringe for cryopreservation, characterized by comprising a barrel having an injection port and an opening, a gasket slidably accommodated in the barrel, a plunger connected to the gasket, and a cap for sealing the injection port of the barrel, wherein the opening of the barrel is sealed only by the gasket. The syringe is excellent in usability, durability, and safety.
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
36.
Printed base material and method for producing the same
A printed base material includes a printed area on a base material. The printed area includes a differently colored printed area having different colors separated by a clearance.
According to the present invention, a syringe is provided for the cryopreservation of cells, nucleic acids, or proteins, the syringe being characterized by comprising: a barrel having a discharge section and an opening, and accommodating cells, nucleic acids, or proteins; a gasket slidably accommodated in the barrel; a plunger connected to the gasket; and a cap that seals the discharge section of the barrel, the barrel being formed from a fluororesin, and the gasket being formed from a fluororesin or a polyethylene resin. This syringe excels in usability, durability, and safety.
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
A nutritional formulation for use in suppressing a symptom of refeeding syndrome includes a protein and/or an amino acid in a total amount of 3.5 g or less per 100 kcal. A method for providing nutritional support while suppressing symptoms of refeeding syndrome in patients in an undernutrition state includes the use of the nutritional formulation which includes a protein and/or an amino acid in a total amount of 3.5 g or less per 100 kcal.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 3/02 - Nutriments, p. ex. vitamines, minéraux
A61K 31/718 - Amidon ou amidon dégradé, p. ex. amylose, amylopectine
A61K 31/7016 - Disaccharides, p. ex. lactose, lactulose
A61K 31/7004 - Monosaccharides ayant uniquement des atomes de carbone, d'hydrogène et d'oxygène
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/405 - Acides indole-alkanecarboxyliquesLeurs dérivés, p. ex. tryptophane, indométhacine
A61K 31/4172 - Acides imidazole-alkanecarboxyliques, p. ex. histidine
A61K 31/401 - ProlineSes dérivés, p. ex. captopril
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
Provided are an adhesion preventing agent and an adhesion preventing method using the same. Specifically, provided are an adhesion preventing agent, including at least one anionized nanomaterial selected from the group consisting of anionized nanocellulose and anionized nanochitin, and an adhesion preventing method using the adhesion preventing agent.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparation for
children and infants; amino acid preparations;
chemico-pharmaceutical preparations; dietary supplements for
human beings; nutritional supplements; nutritional
supplements for children and infants; dietetic foods adapted
for medical purposes; dietetic beverages adapted for medical
purposes; pharmaceutical preparations and substances for the
treatment of kidney diseases; pharmaceutical preparations
for the treatment of malnutrition; intravenous fluids used
for nutrition being pharmaceuticals; infusion solution being
pharmaceuticals.
41.
ELECTRICAL STIMULATION ELECTRODE AND ELECTRODE ATTACHMENT SUPPORTER
An electrical stimulation electrode according to the present invention includes: a base material which is formed from a sheet-shaped insulating material having a first surface to be pressed against a living body surface and a second surface to the opposite side from the first surface; a conductive part which is formed from a conductive material on the first surface of the base material; a connection part which is formed on the second surface of the base material and is conductive to the conductive part; a plurality of slits which are formed in the base material and in which a region for ensuring electrical connection between the connecting part and the conductive part is formed between the plurality of slits.
The present invention provides an improved encapsulated pancreatic islet. A formulation comprising a core covered with a five-layered membrane, wherein the core comprises one or more pancreatic islets; and the first, third, and fifth membranes from the inner side of the five-layered membrane contain alginic acid, and the second and fourth membranes from the inner side contain polyornithine.
An object of the present invention is to provide a method for efficiently producing heparosan by improving a heparosan-producing ability through genetic modification of a bacterium of the genus Escherichia which has a heparosan-producing ability. The present invention relates to a bacterium of the genus Escherichia which has a genetic modification that increases an expression of a kpsS gene, and which has a heparosan-producing ability; and a method for producing heparosan using the bacterium.
A urinary catheter cap includes a main body that includes a urine introduction passage including a connection hole configured to be connected to a urinary catheter and a drain hole for draining urine, a lid portion that has a tubularly formed portion having a first end portion at the drain hole side and a second end portion at an opposite side and opens and closes the drain hole, a partition portion that divides the tubular portion of the lid portion into a plurality of spaces, and a hydrophobic film that is formed such that the hydrophobic film blocks at least two or more of the spaces at the second end portion of the lid portion. The partition portion may include a partitioning plate that is installed between a plurality of locations of an inner circumferential portion of the tubular portion of the lid portion.
Corynebacterium, which contains a gene encoding an ATP sulfurylase and a gene encoding an APS kinase, which are expressible, and in which a cell plasma membrane of the transformant (a) is substance-permeable, or a treated matter of the transformant (a), and conducting a reaction for producing PAPS by using a reaction solution containing ATP or an ATP source, a sulfate ion source, and the transformant (a) or the treated matter thereof.
Low molecular weight heparin (LMWH) suitable for equivalent use to USP enoxaparin sodium is prepared from a starting material isolated from engineered E. coli K5 capsular polysaccharide, e.g., E. coli K5 heparosan. The E. Coli CPS is treated with acids to remove 3-deoxy-D-manno oct-2-ulosonic acid (Kdo) residues, and further hydrolyzed via alkali treatment to form low molecular weight N-sulfo, N-acetyl heparosan (LMW-NSNAH) having molecular weight and N-acetylation comparable to enoxaparin. The LMW-NSNAH is converted to LMWH via a series of enzymatic modifications by C5-epimerase, 2-O-, 6-O-, and 3-O-sulfotransferases. Compositions including the LMWH are prepared without the use of porcine-derived heparin, and thus benefit from better source material availability, better control of manufacturing processes, reduced concerns about contamination, adulteration or animal virus, or impurities. Further, the LMWH product is demonstrated to be structurally and functionally comparable traditional pharmaceutical LMWHs.
Low molecular weight heparin (LMWH) suitable for equivalent use to USP enoxaparin sodium is prepared from a starting material isolated from engineered E. coli K5 capsular polysaccharide, e.g., E. coli K5 heparosan. The E. Coli CPS is treated with acids to remove 3-deoxy-D-manno oct-2-ulosonic acid (Kdo) residues, and further hydrolyzed via alkali treatment to form low molecular weight N-sulfo, N-acetyl heparosan (LMW-NSNAH) having molecular weight and N-acetylation comparable to enoxaparin. The LMW-NSNAH is converted to LMWH via a series of enzymatic modifications by C5-epimerase, 2-O-, 6-O-, and 3-O-sulfotransferases. Compositions including the LMWH are prepared without the use of porcine-derived heparin, and thus benefit from better source material availability, better control of manufacturing processes, reduced concerns about contamination, adulteration or animal virus, or impurities. Further, the LMWH product is demonstrated to be structurally and functionally comparable traditional pharmaceutical LMWHs.
The present invention reduces an error in the return temperature for returning to a state in which current is applied from a state in which current is cut off. Provided is a breaker in which a bi-metal that deforms between an inverted shape and a non-inverted shape with the ambient temperature deforms a movable contact metal plate and switches a contact on/off, wherein: the movable contact metal plate has an arm part at the tip of which is provided a movable contact and a fixed part which is fixed to a case; the arm part is provided with a deformable arm part which deforms with pressing by the bi-metal and a fixed arm part which is separated from the deformable arm part via a slit; and a contact part that determines the position of contact with the bi-metal is provided to the fixed arm part which does not move along with the deformable arm part.
The present invention addresses the problem of providing a composition that is used in order to prevent or suppress refeeding syndrome. Provided as a solution to the problem is a composition that is used to prevent or suppress refeeding syndrome, the composition containing an mTOR inhibitor.
A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
50.
METHOD OF PRODUCING CAPSULE COMPRISING PANCREATIC ISLET
The present invention provides an improved method for producing pancreatic islet-containing capsules.
The present invention provides an improved method for producing pancreatic islet-containing capsules.
A method for producing pancreatic islet-containing capsules, comprising the steps of:
The present invention provides an improved method for producing pancreatic islet-containing capsules.
A method for producing pancreatic islet-containing capsules, comprising the steps of:
(a) preparing a sodium alginate solution A containing pancreatic islets at a concentration of 10,000 IEQ/mL or more;
The present invention provides an improved method for producing pancreatic islet-containing capsules.
A method for producing pancreatic islet-containing capsules, comprising the steps of:
(a) preparing a sodium alginate solution A containing pancreatic islets at a concentration of 10,000 IEQ/mL or more;
(b) adding the sodium alginate solution to a divalent cation solution dropwise, and collecting gelled particles;
The present invention provides an improved method for producing pancreatic islet-containing capsules.
A method for producing pancreatic islet-containing capsules, comprising the steps of:
(a) preparing a sodium alginate solution A containing pancreatic islets at a concentration of 10,000 IEQ/mL or more;
(b) adding the sodium alginate solution to a divalent cation solution dropwise, and collecting gelled particles;
(c) adding the particles collected in step (b) to a poly-L-ornithine solution A, followed by stirring and then collecting particles;
The present invention provides an improved method for producing pancreatic islet-containing capsules.
A method for producing pancreatic islet-containing capsules, comprising the steps of:
(a) preparing a sodium alginate solution A containing pancreatic islets at a concentration of 10,000 IEQ/mL or more;
(b) adding the sodium alginate solution to a divalent cation solution dropwise, and collecting gelled particles;
(c) adding the particles collected in step (b) to a poly-L-ornithine solution A, followed by stirring and then collecting particles;
(d) adding the particles collected in step (c) to a sodium alginate solution B, followed by stirring and then collecting particles; and
The present invention provides an improved method for producing pancreatic islet-containing capsules.
A method for producing pancreatic islet-containing capsules, comprising the steps of:
(a) preparing a sodium alginate solution A containing pancreatic islets at a concentration of 10,000 IEQ/mL or more;
(b) adding the sodium alginate solution to a divalent cation solution dropwise, and collecting gelled particles;
(c) adding the particles collected in step (b) to a poly-L-ornithine solution A, followed by stirring and then collecting particles;
(d) adding the particles collected in step (c) to a sodium alginate solution B, followed by stirring and then collecting particles; and
(e) adding the particles collected in step (d) to a sodium citrate solution, followed by stirring and then collecting particles.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
The object of the present invention is to provide an antiseptic composition that can reduce the risk of an incise drape coming off from the skin, without adversely affecting microbicidal activity, even when the incise drape is affixed to skin surface after application of the antiseptic composition, and/or exerts more effective microbicidal activity. A composition comprising a microbicide and a sugar alcohol is used as the antiseptic composition.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61L 2/18 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des substances chimiques des substances liquides
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
The present invention addresses the problem of providing a disinfecting composition that, when an incise drape is placed on the skin surface on which the disinfecting composition has been applied, can reduce the risk of the incise drape peeling from the skin without detrimentally affecting the bactericidal potency thereof, and/or realize more effective bactericidal potency. The disinfecting composition contains a bactericidal agent and a sugar alcohol.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61L 2/18 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des substances chimiques des substances liquides
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
53.
URINARY CATHETER AND JOINTING PART FOR URINARY CATHETER
A urinary catheter that comprises: a catheter body comprising a flexible shaft, which has a first end to be indwelled in a patient's bladder and a second end on the opposite side thereof and which also has an inner lumen for urinary drainage, and a base which is connected to the second end of the shaft and has an inner urinary drainage channel communicating with the lumen for urinary drainage; and a jointing part comprising a soft first part, which is formed in the shape of a cylinder fitted to the shaft and disposed at the connection section between the shaft and the base, and a hard second part which integrally holds the boundary between the first part and the base in such a manner that a portion of the first part is exposed as a free part on the first end side of the shaft and which is fixed to the base.
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
The present invention addresses the problem of providing: a novel method for supplying nutrients while preventing or suppressing the development of refeeding syndrome in a subject with a nutrient-poor condition; and an enteral nutrient preparation that can be used in the method. As a solution for the problem, an enteral nutrient preparation is provided, which comprises a protein, a lipid, and optionally an amino acid, in which a protein other than a milk-derived protein makes up 90% by weight or more of the protein, and (a) the amino acid score of a mixture of the protein and the amino acid is 100 and the calorific ratio of the lipid is 40% or more or (b) the amino acid score of a mixture of the protein and the amino acid is less than 100 and the calorific ratio of the lipid is 15% or more.
A23L 33/115 - Acides gras ou leurs dérivésGraisses ou huiles
A23L 33/125 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sirops d'hydrate de carboneModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des sucresModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des alcools de sucreModification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs contenant des hydrolysats d'amidon
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
A61K 31/23 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides acycliques, p. ex. pravastatine d'acides ayant un groupe carboxyle lié à une chaîne d'au moins sept atomes de carbone
A61K 36/48 - Fabaceae ou Leguminosae (famille du pois ou des légumineuses)CaesalpiniaceaeMimosaceaePapilionaceae
A61K 38/02 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
A61K 38/39 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine, globuline insoluble à froid [CIG]
A61P 3/02 - Nutriments, p. ex. vitamines, minéraux
A61P 3/12 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase des électrolytes
This bottle container manufacturing method comprises: a first step of introducing a cylindrical translucent resin material into a cavity of a blow molding mold including a pair of mold bodies and a transfer part provided on a cavity surface of at least one of the pair of mold bodies and having a minute irregularity pattern formed thereon; a second step of molding a bottle body by inflating the translucent resin material introduced into the cavity by blow molding and directly transferring the minute irregularity pattern of the transfer part onto an outer surface of the bottle body; and a third step of extracting the bottle body including a decorative part that includes a minute irregularity shape corresponding to the minute irregularity pattern and partially decorates the outer surface by showing a structural color.
B65D 23/00 - Parties constitutives des bouteilles ou des pots non prévues ailleurs
B29C 33/42 - Moules ou noyauxLeurs détails ou accessoires caractérisés par la forme de la surface de moulage, p. ex. par des nervures ou des rainures
B29C 49/42 - Éléments constitutifs, détails ou accessoiresOpérations auxiliaires
B29C 49/52 - Moules comportant des moyens de décoration ou d'impression
B65D 1/00 - Réceptacles rigides ou semi-rigides ayant des corps d'une seule pièce formés, p. ex. par coulage d'un matériau en métal, par moulage d'un matériau plastique, par soufflage d'un matériau vitreux, par coulage d'un matériau en céramique, par moulage d'un matériau fibreux cuit ou par étirage d'un matériau en feuille
B65D 1/02 - Bouteilles ou réceptacles similaires, à cols ou à ouvertures rétrécies analogues, conçus pour verser le contenu
58.
ELECTRICAL STIMULATION THERAPEUTIC DEVICE AND ELECTRICAL STIMULATION THERAPEUTIC METHOD
An electrical stimulation therapeutic device includes a pair of application electrodes which are disposed at the back of a sacral bone of a person to be treated and supplies an electrical stimulation signal from the back of the sacral bone, a detection electrode which is disposed on a surface of a toe of the person to be treated and detects a myoelectric signal of the toe, a display portion which determines whether the myoelectric signal of the toe is generated in response to the stimulation signal, and a myoelectric signal processing portion which processes the myoelectric signal detected by the detection electrode to display it visually on the display portion, in which the myoelectric signal processing portion does not detect the myoelectric signal of the toe during a predetermined detection stop period of time from output of the stimulation signal, and the detection stop period of time is set on the basis of a quotient (x/v) obtained when a distance (x) from a sacral bone of a human body to a surface of a toe is divided by a transmission velocity (v) of a nerve which passes through the sacral bone of the human body or the vicinity of the sacral bone.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
[Problem] To provide: a liquid agent container formed from a multilayer film in which polybutylene terephthalate is used in an outer layer, the liquid agent container being such that elution of a component derived from the polybutylene terephthalante into a liquid contained in the liquid agent container through the multilayer film is suppressed or prevented; and a multilayer film for forming such a liquid agent container. [Solution] Provided is a multilayer film obtained by laminating at least (1) a layer that contains polybutylene terephthalate, (2) a layer that contains a cyclic-olefin-based polymer, (3) a flexible layer that contains an ethylene-based resin, and (4) a layer that contains a polyolefin, the multilayer film being such that the layer (1), the layer (2), and the layer (4), which forms one surface of the multilayer film, are laminated in the stated order. Also provided is a liquid agent container formed from the multilayer film such that the layer (4) serves as the innermost layer.
An electroconductive rubber sheet includes a sheet-shaped rubber base material having electrical conductivity and an electroconductive sheet embedded in the rubber base material. This electroconductive rubber sheet can be obtained according to a method for producing an electroconductive rubber sheet that includes, for example, a step of placing an electroconductive sheet and a sheet-shaped rubber material, which has electrical conductivity and an opening in a central portion of the sheet-shaped rubber material, on a mold and a step of pressing the electroconductive sheet and the rubber material at a temperature at which the rubber material is softened.
This gas vent valve includes: a base film in which a ventilation hole for gas ventilation is formed; a cover film which is layered on the base film so as to cover the ventilation hole, is composed of linear low-density polyethylene, and is adhered to the base film by a pair of first adhesion sites that oppose each other in a first direction across the ventilation hole; a gas discharge path, which is formed at a site sandwiched by the pair of first adhesion sites between the base film and the cover film, is formed along a second direction intersecting the first direction so as to overlap the ventilation hole, and has a first end and a second end opposite thereto in the second direction, at least one of the first end and the second end being an open end of the gas discharge path; and a second adhesion site which is disposed on the open end side with respect to the ventilation hole in the gas discharge path, and is formed by partial adhesion between the cover film and the base film.
B65D 51/16 - Fermetures non prévues ailleurs avec moyens pour laisser partir l'air ou le gaz
B65D 85/50 - Réceptacles, éléments d'emballage ou paquets spécialement adaptés à des objets ou à des matériaux particuliers pour organismes vivants, objets ou matériaux sensibles aux changements d'ambiance ou de conditions atmosphériques, p. ex. pour animaux terrestres, oiseaux, poissons, plantes aquatiques, plantes non aquatiques, oignons de fleurs, fleurs coupées ou feuillage
B65D 81/26 - Adaptations pour empêcher la détérioration ou l'altération du contenuApplications au réceptacle ou au matériau d'emballage d'agents de conservation des aliments, de fongicides, d'insecticides ou de produits repoussant les animaux avec dispositifs pour évacuer ou absorber les fluides, p. ex. s'écoulant du contenuEmploi de produits empêchant la corrosion ou de dessiccateurs
An object of the present invention is to provide a pharmaceutical composition containing mesenchymal stem cells that exhibit excellent therapeutic effects on various diseases, injured parts, wounds and decubitus. The present invention relates to a pharmaceutical composition for treating a non-porcine animal, the pharmaceutical composition includes a neonatal pig-derived mesenchymal stem cell which produces at least one humoral factor selected from TGF-β1, TGF-β2, VEGF-A and VEGF-C.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
63.
ELECTRICAL STIMULATION DEVICE AND PATIENT MANAGEMENT SYSTEM
An electrical stimulation device that has a stimulation electrode that can supply an electrical stimulation signal. The electrical stimulation device includes: a storage unit that stores a scheduled hospital visit date for a patient that is a user of the electrical stimulation device; and a hospital visit alert provision means that provides the patient with a hospital visit alert that encourages a hospital visit when the patient has not made a hospital visit despite the passage of the scheduled hospital visit date. A patient management system that includes: a communication means for communicating with the electrical stimulation device; and a hospital visit date setting means that sets the scheduled hospital visit date for the patient at the electrical stimulation device via the communication means.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
G16H 10/00 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients
64.
TREHALOSE-CONTAINING LIQUID FOR MAMMALIAN CELL PRESERVATION
The present invention addresses the problem of providing, for instance, a mammalian cell preservation solution that can effectively suppress a decrease in cell viability occurring when mammalian cells are preserved in liquid or a decrease in self-renewal potential occurring when mammalian stem cells are preserved in liquid, and that is less likely to cause a harmful effect on the life of a mammal at the time of in vivo administration of mammalian cells to the mammal. This solution involves preserving a mammalian cell by using a mammalian cell preservation solution comprising trehalose or a derivative thereof, or a salt thereof and a hydrogen carbonate, such as sodium bicarbonate, as a pH modifier, and having a pH of from 6.5 to 8.5.
This electrical stimulation therapy device comprises: a pair of stimulation electrodes that are disposed on the skin on the back of the sacrum of a patient and that provide electrical stimulation to the nerves passing through the sacrum or near the sacrum; a detection electrode that is disposed near the bladder in the lower abdomen of the patient and that detects myoelectric signals around the bladder of the patient; and a control unit that is electrically connected to the pair of stimulation electrodes and to the detection electrode. The control unit intermittently applies a stimulation voltage to the pair of stimulation electrodes and detects, via the detection electrode, changes in the myoelectric signals around the bladder, such changes being induced by relaxation and contraction of the bladder as generated through the intermittent application of the stimulation voltage.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Antiseptics; cleansing preparations for skin and mucous membranes for medical purposes; antiseptic preparations for skin and mucous membranes; antiseptic preparations for surgical sites; antiseptic preparations for use in preventing infection in wounds; antiseptic preparations for medical instruments; antiseptic preparations used for hospital operating rooms and hospital rooms
67.
ELECTRICAL STIMULATION DEVICE, PATIENT MANAGEMENT SYSTEM, AND PATIENT TREATMENT INFORMATION MANAGEMENT METHOD
In order to make it possible to easily position a first electrode at a suitable position and obtain an effective stimulating effect by electrical stimulation, an electrical stimulation device includes a control unit. The control unit is configured to: perform a negative voltage application process of applying a voltage between the first electrode (63) and a second electrode (38) so that the first electrode (63) is at a negative potential relative to the second electrode (38), and a positive voltage application process of applying a voltage between the first electrode (63) and the second electrode (38) so that the first electrode (63) is at a positive potential relative to the second electrode (38); make a comparison between the waveform of a first biological signal from a site subject to detection detected during the negative voltage application process and the waveform of a second biological signal from the site subject to detection detected during the positive voltage application process; determine, on the basis of the comparison between the waveform of the first biological signal and the waveform of the second biological signal, the direction of displacement of the attachment position of the first electrode with respect to a site subject to stimulation; and generate a guidance information signal indicating the direction in which the attachment position of the first electrode (63) is to be adjusted.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
An object of the present invention is to provide a novel preservation solution for preserving mammalian cells over a long period of time in a non-frozen state. Ascorbic acid and/or niacin is added to an isotonic solution to prepare a preservation solution. The preservation solution is mixed with platelets and preserved under shaking. Decrease in the functions and viability of the platelets can thereby be suppressed for at least 10 days. Alternatively, the aforementioned preservation solution is mixed with mesenchymal stem cells, megakaryocytes, or T cells and preserved in a non-frozen state. Decrease in the functions and viability of these cells can thereby be suppressed for at least several days to several tens of days.
In the present invention, switching to an off state is carried out at a set temperature while increasing maximum current. This non-conductive type breaker includes: a case 1; a fixed contact metal plate 4 that is fixed to the case 1 and that includes a fixed contact 5; a movable contact metal plate 6 that includes a movable contact 7 that contacts the fixed contact 5 in an ON/OFF state; and a bimetal 8 that is disposed between the movable contact metal plate 6 and the fixed contact metal plate 4 and, in a state exceeding a set temperature, deforms from a non-inverted shape to an inverted shape. In the non-inverted shape of the bimetal 8, the elasticity of the movable contact metal plate 6 brings the movable contact 7 into contact with the fixed contact 5, thereby placing the movable contact 7 in the ON state, and in the inverted shape of the bimetal 8, the bimetal 8 presses the movable contact metal plate 6, thereby switching the movable contact 7 to the OFF state. The movable contact metal plate 6 includes a recess 31 on a surface thereof, and a recess elastic deformation section 30 which is thinly formed due to the recess 31.
A liquid material including a polysaccharide is manufactured by creating a mixture of polysaccharides and an aqueous solvent or an aqueous cosolvent with organic solvents at a temperature at which gelation does not occur. The mixture is also irradiated at this lower temperature, such as with ultrasound waves in combination with stirring and/or bubbling of inert gases, to apply ultrasound to a mixture of. Compared with conventional reactions with low concentration solutions, the product yield and advantageous mechanical properties are significantly increased. Depolymerization (decomposition, disassembly) of polysaccharide in the liquid material does not occur to any substantial degree, and the molecular structure of the polysaccharide is maintained. Further, the liquid material does not gel even when the temperature is raised, and thus, its fluidity is maintained, despite polysaccharides being maintained at a high concentration. The liquid material is applicable to myriad industries, including pharmaceuticals and health foods.
C08J 3/02 - Production de solutions, dispersions, latex ou gel par d'autres procédés que ceux utilisant les techniques de polymérisation en solution, en émulsion ou en suspension
C08J 3/28 - Traitement par ondes énergétiques ou par rayonnement de particules
C08B 37/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
05 - Produits pharmaceutiques, vétérinaires et hygièniques
29 - Viande, produits laitiers et aliments préparés ou conservés
30 - Aliments de base, thé, café, pâtisseries et confiseries
32 - Bières; boissons non alcoolisées
Produits et services
Dietetic beverages adapted for medical purposes; dietetic
foods adapted for medical purposes; beverages for babies;
food for babies; lacteal flour for babies; dietary and
nutritional supplements consisting primarily of proteins,
fats and/or carbohydrates in liquid, jelly, gel or powder
form; dietary and nutritional supplements; dietary
supplement drinks; dietary supplement drink mixes; powdered
nutritional supplement drink mix. Jellies for food; jellies, jams, compotes; gelatine for
food; meat jellies; fish jellies; fruit jellies; vegetable
jellies; kanten [dried pieces of agar jelly]; meat jellies
containing collagen peptides; fish jellies containing
collagen peptides; fruit jellies containing collagen
peptides; vegetable jellies containing collagen peptides;
protein milk; soya milk in jelly; soya-based snack foods;
milk-based beverages flavored with coffee; milk-based
beverages containing fruit juice; fruit-based,
vegetable-based, bean-based or nut-based snacks. Puddings; jellies [confectionery]; bavarian creams;
confectionery; bread and buns; porridge; processed grains;
boxed lunches consisting of rice, with added meat, fish or
vegetables; instant confectionery mixes; ice cream mixes;
sherbet mixes; coffee; cocoa; tea; sweets; artificial
coffee; pastries; processed cereals; preparations made from
rice; wheat, processed; ready-to-eat cereals; gluten-free
cereal products; cereal bars. Soft drinks; fruit juices; vegetable juices [beverages];
whey beverages; beer; extracts of hops for making beer;
fruit and vegetable smoothies; non-alcoholic beverages for
nutritional purposes; non-alcoholic beverages; smoothies;
energy drinks; isotonic beverages; soft drinks in jelly;
fruit juices in jelly; vegetable juices in jelly
[beverages]; whey beverages in jelly; isotonic beverages in
jelly; concentrates, syrups and powders used in the
preparation of soft drinks; syrups and other non-alcoholic
preparations for making beverages; powders used in the
preparation of non-alcoholic beverages for nutritional
purposes; powders used in the preparation of fruit-based
beverages; syrups for beverages; soft drinks in powder form;
fruit juices in powder form; vegetable juices in powder form
[beverages]; whey beverages in powder form; isotonic
beverages in powder form; non-alcoholic beverages, other
than for dietary or medical purposes; powder used in the
preparation of non-alcoholic beverages, other than for
dietary or medical purposes; soft drink mixes;
non-carbonated soft drinks; coffee-flavored soft drinks;
fruit-flavored soft drinks; vitamin fortified soft drinks;
sports drinks.
73.
MEDICAL TUBE AND MEDICAL TUBE POSITION DETECTION SYSTEM
To provide such a medical tube that a position of a distal end part thereof is easily detectable from an outside of a body of a patient, regardless of orientation of the distal end part inserted into the body. A medical tube including: a main body part having a tubular shape; at least one opening formed in a side face of a main body part; and a light transmitting part formed at one end of the main body part, the light transmitting part having a hemispherical face shape, the light transmitting part being configured to emit light from a light source.
A drug administration device according to the present invention is a drug administration device for subcutaneously administering a drug, and includes a main body portion configured to be arranged on skin of a patient, and a movable portion to which at least one needle member protruding toward the skin is attached. The movable portion is configured to be capable of being moved between a first position that is spaced apart from the skin and a second position that is near the skin. The leading end portion of the needle member is to be inserted into the skin when the movable portion is located at the second position. The drug is to be discharged from a hole provided in the needle member.
Provided is a novel printed substrate. This printed substrate is provided with a printed section disposed on the substrate, wherein the printed section includes a multicolor printed section in which different colors are printed, separate from each other by a clearance.
B05D 1/26 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces par application de liquides ou d'autres matériaux fluides, à partir d'un orifice en contact ou presque en contact avec la surface
B05D 5/06 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces pour obtenir des effets, finis ou des structures de surface particuliers pour obtenir des effets multicolores ou d'autres effets optiques
B41J 2/01 - Machines à écrire ou mécanismes d'impression sélective caractérisés par le procédé d'impression ou de marquage pour lequel ils sont conçus caractérisés par la mise en contact sélective d'un liquide ou de particules avec un matériau d'impression à jet d'encre
B41M 3/00 - Procédés d'impression pour des travaux imprimés d'un genre particulier, p. ex. motifs
B41M 5/00 - Procédés de reproduction ou méthodes de reproduction ou de marquageMatériaux en feuilles utilisés à cet effet
Provided is a novel printed substrate. This printed substrate is provided with a printed section disposed on the substrate, wherein the printed section includes a multicolor printed section in which different colors are printed, separate from each other by a clearance.
B05D 1/26 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces par application de liquides ou d'autres matériaux fluides, à partir d'un orifice en contact ou presque en contact avec la surface
B05D 5/06 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces pour obtenir des effets, finis ou des structures de surface particuliers pour obtenir des effets multicolores ou d'autres effets optiques
B41M 3/00 - Procédés d'impression pour des travaux imprimés d'un genre particulier, p. ex. motifs
B41J 2/01 - Machines à écrire ou mécanismes d'impression sélective caractérisés par le procédé d'impression ou de marquage pour lequel ils sont conçus caractérisés par la mise en contact sélective d'un liquide ou de particules avec un matériau d'impression à jet d'encre
B41M 5/00 - Procédés de reproduction ou méthodes de reproduction ou de marquageMatériaux en feuilles utilisés à cet effet
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Antiseptic and anti-bacterial ointment; medicated ointments for medical purposes for the treatment of dermatological conditions; medicated skin cleanser; medicated skin moisturizer; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for skin wounds
To provide a novel cold remedy or antiviral agent. A cold remedy including a compound represented by general formula (1) or a pharmaceutically acceptable salt thereof.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
To provide a novel cold remedy or antiviral agent. A cold remedy including a compound represented by general formula (1) or a pharmaceutically acceptable salt thereof.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Provided are: a novel method for performing nutrition supply while suppressing the symptoms of refeeding syndrome in patients in a low nutritional state; and a nutrition formulation which can be used in said method. Provided is a nutrition formulation which contains a protein and/or an amino acid in an amount of at most 3.5 g per 100 kcal in the total amount, and is used for suppressing the symptoms of refeeding syndrome.
A61K 31/7004 - Monosaccharides ayant uniquement des atomes de carbone, d'hydrogène et d'oxygène
A61K 38/02 - Peptides à nombre indéterminé d'amino-acidesLeurs dérivés
A61P 3/02 - Nutriments, p. ex. vitamines, minéraux
A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
A61P 7/08 - Substitut de plasmaSolutions de perfusionDyalisats ou hémodyalisatsMédicaments pour le traitement des troubles électrolytiques ou acido-basiques, p. ex. choc hypovolémique
The present invention provides an improved encapsulated islet. This encapsulated islet is a preparation in which a core is coated with five layers of films, the core includes an islet, the first, third, and fifth films from the inside among the five layers of films include alginic acid, and the second and fourth films from the inside include polyornithine.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
The present invention provides an improved encapsulated islet. This encapsulated islet is a preparation in which a core is coated with five layers of films, the core includes an islet, the first, third, and fifth films from the inside among the five layers of films include alginic acid, and the second and fourth films from the inside include polyornithine.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
[OBJECT] To provide a light guide used to facilitate insertion of a medical tube into a body of a patient. [SOLUTION] A light guide to be used for inserting a medical tube into a body for nasogastric tube feeding, the light guide including: a main body part having a long length, the main body part being configured to guide light entering a proximal end part from a light source device, to emit resultant light from a distal end part, wherein the main body part includes a linear part having a predetermined length from the distal end part, and a curved part continuous with the linear part, the curved part having a predetermined curvature radius, the linear part has a length in a range of from 40 mm to 100 mm, and the curved part has a curvature radius in a range from 105 mm to 225 mm
The present invention provides an adhesion-preventing agent and a method for preventing adhesion that uses the same. The present invention relates to: an adhesion-preventing agent containing at least one anionized nano ma-terial selected from the group consisting of anionized nanocellulose and anionized nanochitin; and a method for preventing adhesion using the adhesion-preventing agent.
The present invention provides an adhesion-preventing agent and a method for preventing adhesion that uses the same. The present invention relates to: an adhesion-preventing agent containing at least one anionized nano material selected from the group consisting of anionized nanocellulose and anionized nanochitin; and a method for preventing adhesion using the adhesion-preventing agent.
Provided is an electrical stimulation device capable of determining whether or not a conductive sheet to be used meets predetermined use conditions. An electrical stimulation device that has a pad-shaped application electrode capable of supplying an electrical stimulation signal, and is used with a replaceable conductive sheet attached to the application electrode, the electrical stimulation device comprising: a detection unit that detects an object to be detected that is attached to the conductive sheet; a determination unit that determines whether or not the conductive sheet meets predetermined use conditions, on the basis of the detection result of the detection unit; and a notification unit that notifies that the conductive sheet is not qualified when the determination unit determines that the conductive sheet is not qualified.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
The purpose of the present invention is to provide a viscoelastic composition having excellent operability, which is suitable for use in securing the field of view of an endoscope when opaque dark-colored liquid accumulates inside a canal and obstructs the field of view of the endoscope, the viscoelastic composition securing the field of view by pushing the liquid aside, and to provide a method for securing the field of view of an endoscope using the viscoelastic composition. The viscoelastic composition for securing the field of view of an endoscope comprises a substance having viscoelastic properties and water, preferably has a hardness of 550 N/m2 or less, a viscosity (25° C.) of 200 to 2,000 mPa·s, and a loss tangent of 0.6 or less, and more preferably has an electrical conductivity of 250 μS/cm or less. The method for securing the field of view of an endoscope comprises feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.
An object of the present invention is to provide a substance capable of effectively suppressing the decrease in cell viability and the cell aggregation that occur when mammalian cells are preserved in a liquid, and less likely to adversely affect, when administered in vivo to a mammal, the body of the mammal, and a mammalian cell preservation liquid containing such a substance, and the like. Use of a liquid containing acarbose or a salt thereof and/or stachyose or a salt thereof for preserving a mammalian cell can effectively suppress the decrease in cell viability and the cell aggregation that occur when mammalian cells are preserved in a liquid. Further, the mammalian cell preserved in the liquid can be directly administered in vivo to a mammal, without being transferred into a new transplantation liquid.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
An electrical stimulation treatment device includes a pair of application electrodes which are disposed at a site of the skin of a person to be treated where an electrical stimulation is to be given and which supply the electrical stimulation to the skin and a control unit which is connected electrically to the application electrodes to control a magnitude of a stimulation voltage which is supplied to the application electrodes, in which the control unit includes a calculation means for calculating a magnitude of the stimulation voltage which is to be output, depending on a first maximum stimulation voltage set for each person to be treated and an elapsed time or a stimulation frequency from the start of a stimulation session of a predetermined time, and an output means for outputting the stimulation voltage while increasing the voltage in a stepwise manner based on the calculation results of the calculation means.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p. ex. stimulateurs cardiaques
This urinary catheter cap comprises: a main body that includes a urine introduction path including a connection hole to be connected to a urinary catheter and a discharge hole for discharging urine; a lid part that includes a portion having a tubular shape with a first end portion on the discharge hole side and a second end portion on the opposite side, and opens and closes the discharge hole; a partition part that partitions the tubular portion of the lid part into a plurality of spaces; and a hydrophobic film formed so as to plug two or more spaces at the second end portion of the lid part. The partition part may comprise a partitioning plate bridged between a plurality of sites on the inner circumferential surface of the tubular portion of the lid part.
A61M 39/20 - Couvercles ou bouchons d'obturation pour connecteurs ou extrémités ouvertes de tubes
A61F 2/04 - Éléments ou organes creux ou tubulaires, p. ex. vessies, trachées, bronches ou voies biliaires
A61M 1/00 - Dispositifs de succion ou de pompage à usage médicalDispositifs pour retirer, traiter ou transporter les liquides du corpsSystèmes de drainage
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Dietetic beverages adapted for medical purposes; dietetic
foods adapted for medical purposes; beverages for babies;
food for babies; lacteal flour for babies; nutritional
supplements consisting primarily of proteins, fats and/or
carbohydrates in liquid, jelly, gel or powder form;
nutritional supplements; dietary supplements for humans;
dietary supplement drinks; dietary supplement in liquid,
jelly, gel or powder form; dietary supplement drink mixes;
powdered nutritional supplement drink mix.
93.
METHOD FOR PRODUCING HEPAROSAN AND BACTERIUM OF GENUS ESCHERICHIA HAVING HEPAROSAN-PRODUCING ABILITY
An object of the present invention is to provide a method for efficiently producing heparosan by improving a heparosan-producing ability through genetic modification of a bacterium of the genus Escherichia which has a heparosan-producing ability. The present invention relates to a bacterium of the genus Escherichia which has a genetic modification that increases an expression of a kpsS gene, and which has a heparosan-producing ability; and a method for producing heparosan using the bacterium.
An object of the present invention is to provide a method for efficiently producing heparosan by improving a heparosan-producing ability through genetic modification of a bacterium of the genus Escherichia which has a heparosan-producing ability. The present invention relates to a bacterium of the genus Escherichia which has a genetic modification that increases an expression of a kpsS gene, and which has a heparosan-producing ability; and a method for producing heparosan using the bacterium.
An object of the present invention is to provide a method for easily producing sulfated polysaccharides by reacting a PAPS production/regeneration system utilizing the metabolic activity of a microorganism or a treated matter thereof with a microorganism expressing a sulfation enzyme or a treated matter or extract thereof upon mixing of inexpensive raw materials such as magnesium sulfate. Another object of the present invention is to provide a practical method for producing PAPS from inexpensive raw materials. The present invention relates to a method for producing a sulfated polysaccharide and a method for producing PAPS, the methods comprising a step of preparing a transformant (a) of a bacterium of the genus Corynebacterium, which comprises at least a gene encoding an ATP sulfurylase and a gene encoding an APS kinase which are introduced thereinto in an expressible manner, and in which a cell plasma membrane of the transformant (a) is substance-permeable, or a treated matter of the transformant (a); and a step of conducting a reaction for producing PAPS by using a reaction solution containing ATP or an ATP source, a sulfate ion source, and the transformant (a) or the treated matter thereof.
C12P 19/32 - Nucléotides avec un système cyclique condensé, contenant un cycle à six chaînons, comportant deux atomes d'azote dans le même cycle, p. ex. nucléotides puriques, dinucléotide de la nicotinamide-adénine
96.
METHOD FOR PRODUCING HEPAROSAN AND BACTERIUM OF GENUS ESCHERICHIA HAVING HEPAROSAN-PRODUCING ABILITY
An object of the present invention is to provide a method for efficiently producing heparosan by improving a heparosan-producing ability through genetic modification of a bacterium of the genus Escherichia which has a heparosan-producing ability. The present invention relates to a bacterium of the genus Escherichia which has a genetic modification that increases an expression of a kpsS gene, and which has a heparosan-producing ability; and a method for producing heparosan using the bacterium.
An object of the present invention is to provide a method for easily producing sulfated polysaccharides by reacting a PAPS production/regeneration system utilizing the metabolic activity of a microorganism or a treated matter thereof with a microorganism expressing a sulfation enzyme or a treated matter or extract thereof upon mixing of inexpensive raw materials such as magnesium sulfate. Another object of the present invention is to provide a practical method for producing PAPS from inexpensive raw materials. The present invention relates to a method for producing a sulfated polysaccharide and a method for producing PAPS, the methods comprising a step of preparing a transformant (a) of a bacterium of the genus Corynebacterium, which comprises at least a gene encoding an ATP sulfurylase and a gene encoding an APS kinase which are introduced thereinto in an expressible manner, and in which a cell plasma membrane of the transformant (a) is substance-permeable, or a treated matter of the transformant (a); and a step of conducting a reaction for producing PAPS by using a reaction solution containing ATP or an ATP source, a sulfate ion source, and the transformant (a) or the treated matter thereof.
C12P 19/32 - Nucléotides avec un système cyclique condensé, contenant un cycle à six chaînons, comportant deux atomes d'azote dans le même cycle, p. ex. nucléotides puriques, dinucléotide de la nicotinamide-adénine
98.
METHOD FOR PRODUCING SULFATED POLYSACCHARIDE AND METHOD FOR PRODUCING PAPS
An object of the present invention is to provide a method for easily producing sulfated polysaccharides by reacting a PAPS production/regeneration system utilizing the metabolic activity of a microorganism or a treated matter thereof with a microorganism expressing a sulfation enzyme or a treated matter or extract thereof upon mixing of inexpensive raw materials such as magnesium sulfate. Another object of the present invention is to provide a practical method for producing PAPS from inexpensive raw materials. The present invention relates to a method for producing a sulfated polysaccharide and a method for producing PAPS, the methods comprising a step of preparing a transformant (a) of a bacterium of the genus Corynebacterium, which comprises at least a gene encoding an ATP sulfurylase and a gene encoding an APS kinase which are introduced thereinto in an expressible manner, and in which a cell plasma membrane of the transformant (a) is substance-permeable, or a treated matter of the transformant (a); and a step of conducting a reaction for producing PAPS by using a reaction solution containing ATP or an ATP source, a sulfate ion source, and the transformant (a) or the treated matter thereof.
C12P 19/32 - Nucléotides avec un système cyclique condensé, contenant un cycle à six chaînons, comportant deux atomes d'azote dans le même cycle, p. ex. nucléotides puriques, dinucléotide de la nicotinamide-adénine
99.
MAMMALIAN CELL PRESERVATIVE SOLUTION CONTAINING ACARBOSE AND DEXTRAN
The present invention addresses the problem of providing: a substance which can effectively prevent the decrease in cell survival rate which has been conventionally observed when a mammalian cell is preserved in a liquid, and which is less likely to adversely affect a living body of a mammal when the substance is administered to the mammal in vivo; a mammalian cell preservative solution containing the substance; and others. When a solution containing acarbose or a salt thereof and dextran or a salt thereof is used for the preservation of a mammalian cell, it becomes possible to effectively prevent the decrease in cell survival rate which has been conventionally observed when the mammalian cell is preserved in a liquid. A mammalian cell preserved in the solution can be directly administered to a mammal in vivo without requiring the transfer of the mammalian cell into another liquid for transplantation.
A viscoelastic composition for securing the field of view of an endoscope, the viscoelastic composition comprising a thickening substance and water and having a shear storage modulus G′ of 0.7 Pa or more, and a method for securing the field of view of an endoscope, the method comprising feeding the viscoelastic composition from a proximal part of the endoscope, through a channel, into a distal part of the endoscope.
A61B 1/012 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments caractérisés par les conduits internes ou par leurs accessoires
